Effectiveness of edaravone dexborneol on the outcome of acute cerebral infarction of different degrees
-
摘要: 目的 探讨依达拉奉右莰醇治疗不同程度急性脑梗死的临床疗效。方法 纳入2021年1月至2021年12月徐州医科大学附属医院神经内科急性脑梗死患者180例为研究对象,随机分为2组,分别为对照组和观察组(依达拉奉右莰醇)各90例。比较2组治疗前后的血清炎性因子、神经功能缺损评分。通过美国国立卫生院神经功能缺损量表(NIHSS)评分将急性脑梗死患者细分为轻型(NIHSS≤5分)和中-重型(NIHSS＞5分)2种亚型,再比较不同程度脑梗死患者的2种治疗方法的临床疗效。结果 治疗前2组患者基线资料差异无统计学意义(P＞0.05)。治疗后,2组的炎症因子及NIHSS评分均下降(P＜0.05);与对照组相比,观察组的NIHSS评分和炎性因子水平明显降低(P＜0.05)。观察组中,与轻型亚组相比,中-重型亚组的炎性因子和NIHSS更低(P＜0.05)。结论 依达拉奉右莰醇通过降低炎性因子改善急性脑梗死的神经功能缺损症状,并且对中-重型急性脑梗死症状改善效果更好。Abstract: Objective To investigate the effectiveness of edaravone dexborneol on the outcome of acute cerebral infarction of different degrees.Methods A total of 180 patients with acute cerebral infarction who were admitted to the Affiliated Hospital of Xuzhou Medical University from January 2021 to December 2021 were selected. They were randomly divided into two groups (n=90): a control group and an observation group (edaravone dexborneol). Both groups were compared for serum inflammatory factors and neurological deficit scores before and after treatment. Acute cerebral infarction was subdivided into mild (NIHSS≤5 points) and medium-severe (NIHSS >5 points) subtypes, and then the clinical outcome was compared between the two treatment methods for patients with cerebral infarction of different degrees.Results There was no statistical difference in baseline data between the two groups before treatment (P>0.05). After treatment, inflammatory factors and NIHSS scores decreased in both groups (P<0.05). Compared with the control group, the observation group showed significant decreases in NIHSS scores and inflammatory factor levels (P<0.05). In the observation group, inflammatory factors and NIHSS in the medium-severe subgroup were lower than those in the light subgroup (P<0.05).Conclusions Edaravone dexborneol improves neurological deficits in acute cerebral infarction by reducing inflammatory factors, and is more effective in medium-severe acute cerebral infarction.
-
-
[1] 王陇德,刘建民,杨弋,等.我国脑卒中防治仍面临巨大挑战:《中国脑卒中防治报告2018》概要[J].中国循环杂志,2019,34(2):105-119. [2] Kaur H,Prakash A,Medhi B.Drug therapy in stroke:from preclinical to clinical studies[J].Pharmacology,2013,92(5/6):324-334.
[3] Candelario-Jalil E,Dijkhuizen RM,Magnus T.Neuroinflammation,stroke,blood-brain barrier dysfunction,and imaging modalities[J].Stroke,2022,53(5):1473-1486.
[4] Shin TH,Lee DY,Basith S,et al.Metabolome changes in cerebral ischemia[J/OL].Cells,2020,9(7):1630.
[5] Franke M,Bieber M,Kraft P,et al.The NLRP3inflammasome drives inflammation in ischemia/reperfusion injury after transient middle cerebral artery occlusion in mice[J].Brain Behav Immun,2021,92:223-233.
[6] Savitz SI,Baron JC,Fisher M,et al.Stroke treatment academic industry roundtable X:brain cytoprotection therapies in the reperfusion era[J].Stroke,2019,50(4):1026-1031.
[7] Xu J,Wang AX,Meng X,et al.Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke:a phase III,randomized,double-blind,comparative trial[J].Stroke,2021,52(3):772-780.
[8] 张颖楠,姜扬,任莉,等.依达拉奉右莰醇静脉滴注对急性前循环脑梗死血管内治疗开通良好患者脑损伤的改善作用[J].山东医药,2021,61(18):76-79. [9] 钟迪,张舒婷,吴波.《中国急性缺血性脑卒中诊治指南2018》解读[J].中国现代神经疾病杂志,2019,19(11):897-901. [10] Romano JG,Smith EE,Liang L,et al.Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis:a retrospective analysis of the Get With the Guidelines-Strokeregistry[J].JAMA Neurol,2015,72(4):423-431.
[11] Shibata K,Hashimoto T,Miyazaki T,et al.Thrombolytic therapy for acute ischemic stroke:past and future[J].Curr Pharm Des,2019,25(3):242-250.
[12] 张亚洁,王炎强,牟英峰,等.依达拉奉右莰醇对脑缺血再灌注大鼠焦虑抑郁样行为的影响及机制[J].中华行为医学与脑科学杂志,2022,31(1):17-24. [13] Xu LL,Gao YR,Hu M,et al.Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice[J].Fundam Clin Pharmacol,2022,36(5):790-800.
[14] Hu RY,Liang J,Ding L,et al.Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke[J/OL].Int Immunopharmacol,2022,113(Pt A):109315.
[15] Huang YX,Zhang XJ,Zhang C,et al.Edaravone dexborneol downregulates neutrophil extracellular trap expression and ameliorates blood-brain barrier permeability in acute ischemic stroke[J/OL].Mediators Inflamm,2022,2022:3855698.
[16] Hurford R,Sekhar A,Hughes TAT,et al.Diagnosis and management of acute ischaemic stroke[J].Pract Neurol,2020,20(4):304-316.
-
期刊类型引用(8)
1. 赖针珍，王发明. 安宫牛黄丸联合依达拉奉右莰醇治疗重症脑梗死的临床效果. 医药前沿. 2025(06): 81-84 . 
百度学术
2. 王婷，耿闪，张俐可欣，胡楠，黄海涛. 脑脉利颗粒联合依达拉奉右莰醇注射用浓溶液对急性脑梗死患者神经功能、血液流变学和氧化应激的影响. 现代生物医学进展. 2024(06): 1077-1081 . 百度学术
3. 马彩云，王尚臣，朱倩，姚洁. 急性脑梗死患者血清miRNA-126和miRNA-182表达与卒中后血管性认知功能障碍的关系. 中国急救复苏与灾害医学杂志. 2024(06): 811-815 . 百度学术
4. 嵇继宇，王莉，田小军，王玉梅，苏洲. 依达拉奉右莰醇联合丁苯酞对脑梗死患者血清基质金属蛋白酶、神经损伤因子、内皮功能的影响. 中国合理用药探索. 2024(06): 57-63 . 百度学术
5. 周贺伟，李聪，徐五档. 依达拉奉右莰醇结合rt-PA溶栓方案对急性脑梗死患者脑血流灌注及出血性转化风险的影响. 航空航天医学杂志. 2024(08): 954-957 . 百度学术
6. 苏红. 依达拉奉右莰醇治疗急性脑梗死的有效性和安全性研究. 现代医学与健康研究电子杂志. 2024(15): 92-94 . 百度学术
7. 刘婉谌. 阿替普酶联合依达拉奉治疗脑梗死的药学分析. 航空航天医学杂志. 2024(10): 1201-1203 . 百度学术
8. 南岩岩. 依达拉奉右莰醇联合丁苯酞治疗急性脑梗死患者的疗效分析. 临床研究. 2024(11): 88-91 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 35
- HTML全文浏览量: 1
- PDF下载量: 0
- 被引次数: 8
下载:
.png)
